Tag: Intellia Therapeutics

March 20, 2020

The Rise of CRISPR Technology

CRISPR technology is a rapidly growing component of the genetics industry. Here's what investors need to know about its future...
February 27, 2020

Intellia Announces Q4 and Full-Year 2019 Financial Results

Intellia Therapeutics reported operational highlights and financial results for the fourth quarter and year ended December 31, 2019.
November 13, 2018

CRISPR Trials to Watch in 2018

CRISPR Cas-9 gene editing is finally in clinical studies. Here's an overview of CRISPR genetics testing trials currently in progress.
August 24, 2018

Intellia Therapeutics Presents Progress in Lead In Vivo Program at Cold Spring Harbor Laboratory’s Fourth Meeting on Genome Engineering: The CRISPR-Cas Revolution

Intellia Therapeutics (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology, presented data from studies...
March 14, 2018

Intellia Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results

Intellia Therapeutics (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR technology, announced financial results and...
March 8, 2018

4 Gene Editing Technologies Explained

We look at four types of gene editing currently in clinical trials, as well as the pros and cons of...
February 27, 2018

Intellia Therapeutics Announces Publication in Cell Reports of Preclinical Data Demonstrating Effective CRISPR/Cas9 Genome Editing

Intellia Therapeutics (NASDAQ:NTLA), a leading genome editing company developing curative therapeutics using CRISPR/Cas9 technology, announced that Cell Reports will publish at noon...